duvelisib + BMS-986345

duvelisib + BMS-986345 is an investigational combination therapy consisting of the dual PI3K-delta/gamma inhibitor duvelisib and the oral hypomethylating agent BMS-986345 (an oral formulation of azacitidine). This regimen is being evaluated in a Phase 1 clinical trial (NCT04635813) led by the H. Lee Moffitt Cancer Center and Research Institute for the treatment of relapsed or refractory lymphoid malignancies, including mature T-cell lymphomas. BMS-986345 functions as a DNA methyltransferase inhibitor that incorporates into DNA, leading to hypomethylation and the reactivation of tumor suppressor genes. Duvelisib complements this mechanism by inhibiting the delta and gamma isoforms of phosphoinositide 3-kinase (PI3K), which are critical for the signaling, proliferation, and survival of malignant lymphoid cells. The combination represents an all-oral approach to treating difficult-to-treat hematologic malignancies.

Brand names

CopiktraOnureg

Other names

oral azacitidineduvelisib + oral azacitidine